吲哚布芬治疗急性脑梗死的临床疗效观察

Clinic analysis of treatment of the acute ischemic stroke with indobufen

目的探讨吲哚布芬治疗急性脑梗死患者的I临床疗效。方法入选的170例急性脑梗死患者完全随机分为研究组（82例）和对照组（88例），研究组给予吲哚布芬治疗，对照组给予阿司匹林治疗，余治疗同急性脑梗死常规治疗。对2组治疗前及治疗14d、6周后血小板聚集率[花生四烯酸（AA）诱导法和二磷酸腺苷（ADP）诱导法]、临床症状和不良反应发生率进行比较。结果研究组、对照组治疗后14d,6周时血小板聚集率均低于治疗前[研究组：AA法（15．7±3．5）％、（14．8±3．1）％比（37．8±7．7）％，ADP法（36．7±7．4）％，（40．5±5．6）％比（88．7±8．6）％；对照组：AA法（16．0±2．9）％、（15．5±3．6）％比（42．6±6．8）％，ADP法（39．2±7．0）％，（37．4±4．9）％比（90．3±7．8）％，P〈0．01]；2组治疗后神经功能缺损评分均有显著性好转（P〈0．01）；2组问治疗后血小板聚集率、临床疗效无明显差异（P〉0．05）；研究组未出现严重的不良反应。结论吲哚布芬能显著降低血小板聚集率，与阿司匹林相当，在脑梗死急性期时使用安全性较高。

Objective To investigate the effects and safety of Xinbeiindobufen in patients with acute ischemic stroke disease. Methods A totally of 170 patients with acute ischemic stroke were selected and randomly divided into experiment group （n = 82） and control group （ n = 88 ）. The patients in experiment group were given anti-platelet indobufen and others in control group were given aspirin for 6 weeks. Platelet aggregation, the score of neurology impairment and adverse effects were compared between the two groups. Results After treatment, the platelet aggregation in both groups was lower at 2-week and 6-weeks than before （P 〈 0.01 ）. The score of neurology impairment in the both groups was improved at the 6-weeks （ P 〈 0. 01 ）. There were no significant differences in the platelet aggregation and the score between experiment group and control group （P 〉 0. 05）. Drug related serious adverse effects were not found in the experiment group. Conclusions Indobufen may reduce significantly platelet aggregation among the patients with acute ischemic stroke. The effect on anti-platelet of indobufen is equal to one of aspirin. Indobufen related adverse effects are seldom and minor. Indobufen is safe in treating acute ischemic stroke.